NSPR · XBRL financial data

InspireMD financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (NSPR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021†Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	2,485	4,495	5,171	6,205	7,009	8,979
Cost of goods and services sold	2,402	3,741	4,054	4,398	5,503	6,330
Gross profit	83	754	1,117	1,807	1,506	2,649
Research and development	2,233	5,158	7,810	7,981	13,634	15,003
General and administrative	6,127	7,405	8,356	11,104	15,306	20,707
Total operating expenses	10,463	15,470	19,830	22,950	35,009	52,263
Operating income (loss)	(10,380)	(14,716)	(18,713)	(21,143)	(33,503)	(49,614)
Income tax expense (benefit)	4	45	28	65	59	63
Net income (loss)	(10,544)	(14,918)	(18,491)	(19,916)	(32,005)	(48,786)
Earnings per share, basic USD per share	—	(2.03)	(2.35)	(0.82)	(0.76)	(0.76)
Earnings per share, diluted USD per share	—	—	(2.35)	(0.82)	(0.76)	(0.76)
Weighted average shares, basic thousands of shares	—	7,346	7,872	24,268	41,928	64,326
Weighted average shares, diluted thousands of shares	—	—	7,872	24,268	41,928	64,326

† Share count changed about 1/14 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (NSPR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021†Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	12,645	12,004	4,632	9,640	18,916	8,939
Marketable securities	—	—	—	29,383	15,721	45,272
Accounts receivable	476	1,224	1,034	1,804	1,572	2,168
Inventory	1,415	1,143	1,621	2,106	2,570	3,396
Total current assets	15,339	37,094	21,326	44,159	40,521	61,471
Property and equipment, net	448	632	917	1,060	2,371	3,584
Right-of-use asset	1,265	1,081	1,554	1,473	2,360	2,758
Total assets	17,777	39,712	24,653	47,643	46,807	69,404
Accrued liabilities	886	1,136	554	1,115	1,325	1,545
Total current liabilities	3,705	4,347	5,070	6,020	7,678	10,712
Lease liability, non-current	999	781	1,195	1,038	1,796	2,224
Total liabilities	5,614	6,180	7,260	8,142	10,721	14,203
Accumulated deficit	(168,176)	(183,094)	(201,585)	(221,501)	(253,506)	(302,292)
Total stockholders' equity	12,163	33,532	17,393	39,501	36,086	55,201
Total liabilities and equity	17,777	39,712	24,653	47,643	46,807	69,404
Common shares outstanding (cover page) thousands of shares	117,832	8,322	8,327	23,457	29,690	46,802

† Share count changed about 1/14 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (NSPR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021†Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(10,544)	(14,918)	(18,491)	(19,916)	(32,005)	(48,786)
Stock-based compensation	606	1,576	2,352	4,490	10,138	12,332
Net cash from operating activities	(9,081)	(13,210)	(15,542)	(16,376)	(21,868)	(35,103)
Purchases of property and equipment	88	344	473	381	1,402	1,662
Net cash from investing activities	(187)	(22,457)	8,441	(16,092)	12,641	(30,560)
Proceeds from issuing common stock	—	—	—	—	1,000	1,000
Proceeds from issuing equity	16,395	35,034	—	37,534	16,854	—
Net cash from financing activities	16,395	35,034	(140)	37,534	18,452	55,569
Net change in cash	7,131	(641)	(7,372)	5,008	9,276	(9,977)

† Share count changed about 1/14 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
InspireMD	15,149	1,771	(10,895)*	46.5M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Cytosorbents	4,413	9,633	(583)*	62.8M	7.6 quarters	Q2 FY26 10-QJun 30, 2026
Edap TMS	21,542	13,203	(3,691)*	37.5M	6.5 quarters	Q2 FY26 10-QJun 30, 2026
Myomo	11,219	11,705	(1,944)*	39.6M	6.9 quarters	Q2 FY26 10-QJun 30, 2026
Orchestra BioMed Holdings	20,472	88	(19,332)*	60.1M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
Monogram Technologies	12,834	not reported	(2,297)*	40.6M	5.6 quarters	Q2 FY25 10-QJun 30, 2025
Pro Dex	11,759	20,560	6,490	3.2M	—	Q1 FY27 10-QSep 30, 2026
Encision	72	1,528	(127)*	16.9M	0.6 quarters	Q2 FY26 10-QSep 30, 2025
Sensus Healthcare	15,186	2,290	(3,133)*	16.5M	4.8 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.